Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca, Merck Seal $8.5 Billion R&D Cancer Deal

Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.

Read More »

AstraZeneca lung cancer failure sparks share fall

AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares.

Read More »

Cochlear unveils hearing implants that work directly with Apple’s iPhone

Cochlear Ltd. said it can now stream audio directly from Apple Inc.’s iPhone, iPad and iPod to the microchips in its hearing implants without having to use an additional device.

Read More »

Merck & Co. Plans to File NDA for HIV Treatment Doravirine Based on Phase III Results

HIV-positive patients may soon have a new treatment option that can be taken without food restrictions and has a much lower rate of drug interference with other medications patients may be taking.

Read More »

Safety concerns for Dynavax hep B vaccine

A preliminary advisory committee report by the FDA once again pointed to some serious safety issues with Dynavax Technologies’ troubled hepatitis B treatment Heplisav-B.

Read More »

GlaxoSmithKline’s new boss streamlines R&D

GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.

Read More »

Anthem says may exit more individual markets over Obamacare funding

Anthem Inc. said it may exit more individual Obamacare markets as the future of the national healthcare law and the government subsidies that make insurance affordable for millions of Americans remain up in the air.

Read More »

Obamacare repeal battle back on the Senate floor

After a months-long struggle, Republicans have succeeded in bringing Obamacare repeal legislation – a centerpiece of their 2016 election campaigns – to a debate on the U.S. Senate floor.

Read More »

FDA Head Postpones Layoff Notices of Thousands of Employees

FDA’s commissioner told staff in an email that he intends to delay any labor reductions until the end of September unless Congress authorizes its user fee program to provide the necessary funding.

Read More »

Razorfish Health Announces the Promotion of Keri Hettel to SVP, Analytics and Strategy and Brandon Ashcraft to SVP, Operations

Razorfish Health, a uniquely integrated health and wellness advertising agency, announced the promotion of Keri Hettel to SVP, Analytics and Strategy, and Brandon Ashcraft to SVP, Operations.

Read More »

Klick Health’s Incubated Startup Circulation Announces New Strategic Alliances and Series A Financing Closing

The health marketing and commercialization agency continues focus on growing healthcare commercialization practice and introducing more innovative business models to industry.

Read More »

Insulin resistance linked to lower bone density

Decreasing sensitivity to insulin — often associated with obesity and eventual type 2 diabetes — may also cause young adults to have lower bone mass at a time of life when it should be at its peak, Korean researchers say.

Read More »

Takeda, BioSurfaces Announce Research Program

Takeda and BioSurfaces announced a deal to initiate a research program designed to develop innovative medical devices to treat patients with GI diseases.

Read More »

Eli Lilly Shakes Up Cancer R&D Strategy

Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.

Read More »

Biogen raises 2017 forecast on Spinraza success

Biogen Inc.’s second-quarter 2017 profit smashed estimates, boosted by strong sales of the company’s spinal muscular atrophy (SMA) drug Spinraza, which is priced at $750,000 for the first year of therapy.

Read More »

Japanese Pharma Giant Astellas Sets Up Shop in Cambridge

Japan-based Astellas Pharma is setting up a new facility in Cambridge, Mass. which is in line with the company’s 2016 strategic focus on innovation and enhancing its capabilities in developing dynamic new treatments to address unmet medical needs.

Read More »

Merck & Co. Dealt Another Setback as Its Ace Keytruda Comes Up Short in Head and Neck Cancer Study

Merck’s vaunted PD-1 inhibitor Keytruda suffered another setback when it failed to meet endpoints in a Phase III head and neck cancer study.

Read More »

U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict

A federal jury in Chicago found AbbVie Inc. fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.

Read More »

Discovery Worldwide Names Rico Ricketson as Head of Client Services

Discovery Worldwide, a healthcare communications agency that combines the power of science, storytelling and innovative delivery to move health forward, announces the appointment of Rico Ricketson as Head of Client Services.

Read More »

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin

Pfizer Inc. today announced that the REFLECTIONS B7391003 study — a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab) — met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom